Related references
Note: Only part of the references are listed.Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer
Jarrett J. Failing et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients
Alexandra Giatromanolaki et al.
ANTICANCER RESEARCH (2021)
Beclin 1 Promotes Endosome Recruitment of Hepatocyte Growth Factor Tyrosine Kinase Substrate to Suppress Tumor Proliferation
Asia N. Matthew-Onabanjo et al.
CANCER RESEARCH (2020)
Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration
Alexandra Giatromanolaki et al.
BRITISH JOURNAL OF CANCER (2020)
Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
Daan P. Hurkmans et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade
Pierpaolo Correale et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
Willemijn S M E Theelen et al.
Lancet Respiratory Medicine (2020)
Rectal cancer induces a regulatory lymphocytic phenotype in the tumor-draining lymph nodes to promote cancer cell installation
Alexandra Giatromanolaki et al.
IMMUNOLOGIC RESEARCH (2020)
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
Deborah B. Doroshow et al.
CLINICAL CANCER RESEARCH (2019)
Downregulated expression of human leukocyte antigen class I heavy chain is associated with poor prognosis in non-small-cell lung cancer
Kazuomi Ichinokawa et al.
ONCOLOGY LETTERS (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis
Alexandra Giatromanolaki et al.
MEDICAL ONCOLOGY (2019)
Mechanisms regulating PD-L1 expression on tumor and immune cells
Shuming Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
Yeon Bi Han et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2019)
HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape
Francisco Perea et al.
ONCOTARGET (2018)
PD-L1 in breast cancer: comparative analysis of 3 different antibodies
Tejashree Karnik et al.
HUMAN PATHOLOGY (2018)
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
K. G. Paulson et al.
NATURE COMMUNICATIONS (2018)
An early history of T cell-mediated cytotoxicity
Pierre Golstein et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
Xiaohong Wang et al.
CANCER RESEARCH (2017)
Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis
Alexandra Giatromanolaki et al.
EXPERIMENTAL LUNG RESEARCH (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells
Shalini Sethumadhavan et al.
PLOS ONE (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition
Carolina Pereira et al.
CLINICAL CANCER RESEARCH (2017)
The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer
Roy M. Bremnes et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies
B. Seliger
HLA (2016)
B Lymphocytes and Cancer: A Love-Hate Relationship
Grace J. Yuen et al.
TRENDS IN CANCER (2016)
Increased expression of transcription factor EB (TFEB) is associated with autophagy, migratory phenotype and poor prognosis in non-small cell lung cancer
Alexandra Giatromanolaki et al.
LUNG CANCER (2015)
Beclin 1 regulates growth factor receptor signaling in breast cancer
R. A. Rohatgi et al.
ONCOGENE (2015)
Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer
Takeshi Hanagiri et al.
JOURNAL OF SURGICAL RESEARCH (2013)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells
Bo Li et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection
Luc English et al.
NATURE IMMUNOLOGY (2009)
HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer
Eiki Kikuchi et al.
CANCER SCIENCE (2007)
Share Paper
